Program

Check back for updates on the 2019 Genitourinary Cancers Symposium program.

The 2019 Genitourinary Cancers Symposium will feature an array of multidisciplinary sessions covering prostate, renal, urothelial, penile, testicular, and adrenal cancers. World-renowned faculty will present on the most clinically relevant topics across these disease sites with an emphasis on multimodality therapy and value in cancer care.

7:00 AM-7:55 AM Poster Session C: Renal Cell Cancer
With Complimentary Continental Breakfast Beginning at 6:30 AM
7:00 AM-7:55 AM Trials in Progress Poster Session C: Renal Cell Cancer
With Complimentary Continental Breakfast Beginning at 6:30 AM
7:55 AM-9:30 AM Welcome and General Session 7: Key Questions in Localized Kidney Cancer

Christopher J. Kane, MD—Chair
University of California, San Diego

Lori Wood, MD—Chair
Dalhousie University

Karen E. Knudsen, PhD
Sidney Kimmel Cancer Center at Jefferson
Welcome

Brian M. Shuch, MD
University of California, Los Angeles
When to Obtain Genetic Testing for Syndromic Renal Cell Cancer

Rodney H. Breau, MD
University of Ottawa
Renal Function Preservation in Kidney Cancer: Current Techniques and Biomarkers

Point-Counterpoint: How to Inform the Decision of Partial Versus Radical Nephrectomy

Sarah P. Psutka, MD, MS
University of Washington Medical Center
Informing the Decision Using Data Science

Hendrik Van Poppel, MD, PhD
University Hospitals Leuven
Informing the Decision Using Clinical Trial Evidence

Brian I. Rini, MD
Cleveland Clinic Taussig Cancer Institute
Risk Stratification After Resection of Localized Disease: Which Model to Use and Why

Abstract 627: The UCLA Histo-Genetic Risk Classification (U-HGRC) to predict outcomes of localized clear cell renal cell carcinoma.
First Author: Cedric Michel Lebacle, MD

Panel Question and Answer
9:30 AM-10:00 AM Break
10:00 AM-11:30 AM

General Session 8: Evolving Management of Metastatic Renal Cell Carcinoma

Stephen A. Boorjian, MD—Chair
Mayo Clinic

Julia R. Fielding, MD—Chair
The University of Texas Southwestern Medical Center
 

Samra Turajlic, MD, PhD
The Royal Marsden NHS Foundation Trust
Genetic Evolution of Metastatic Renal Cell Cancer

Questions and Lessons Moving Forward From Carmena: Which Treatment First?

Paul Russo, MD
Memorial Sloan Kettering Cancer Center
Surgeon’s Perspective

Lauren Christine Harshman, MD
Dana-Farber Cancer Institute
Medical Oncologist’s Perspective

Michael B. Atkins, MD
Georgetown University
First-Line Systemic Therapy in the Patient With Intermediate-or Poor-Risk Disease: What Agent Should It be in 2019?

Daniel Yick Chin Heng, MD, MPH
University of Calgary
Beyond First-Line Systemic Therapy for Metastatic Renal Cell Cancer
 

Abstract 541: TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). 
First Author: Brian I. Rini, MD, FACP


Panel Question and Answer

11:35 AM-12:30 PM

Rapid Abstract Session C: Renal Cell Cancer
 

Christian K. Kollmannsberger, MD—Chair
BC Cancer - Vancouver Cancer Center

Abstract 547: Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
First Author: Nizar M. Tannir, MD, FACP

Question and Answer

Abstract 548: Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).
First Author: Rana R. McKay, MD

Question and Answer

Abstract 549: CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
First Author: Funda Meric-Bernstam, MD

Question and Answer

Abstract 550: Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
First Author: Ignacio Duran, MD, PhD

Question and Answer

Abstract 551: Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).
First Author: Yasser Ged, MBBS, MRCP

Question and Answer

12:30 PM-2:00 PM Poster Session C: Renal Cell Cancer
With Complimentary Boxed Lunch
12:30 PM-2:00 PM Trials in Progress Poster Session C: Renal Cell Cancer
With Complimentary Boxed Lunch
12:45 PM- 1:30 PM Poster Walks

Daniel Yick Chin Heng, MD, MPH—Poster Walk Leader

University of Calgary

Sarah Psutka, MD, MS—Poster Walk Leader
University of Washington Medical Center
2:00 PM-3:30 PM Oral Abstract Session C: Renal Cell Cancer
Peter E. Clark, MD—Chair

Levine Cancer Institute, Atrium Health

N. Reed Dunnick, MD—Chair
University of Michigan
 

Abstract 543: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
First Author: Thomas Powles, MD, PhD, FCRP


Abstract 544: Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
First Author: Toni K. Choueiri, MD

Lori Wood, MD
Dalhousie University
Discussion

Abstract 545: A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).
First Author: Thomas Powles, MD, PhD, FCRP
 

Abstract 546: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
First Author: David F. McDermott, MD


Tracy L. Rose, MD
University of North Carolina Hospital
Discussion

Panel Question and Answer
3:30 PM-3:45 PM Break
3:45 PM-5:00 PM

General Session 9: How Can We Better Treat Kidney Cancer?

Peter E. Clark, MD—Chair
Levine Cancer Institute, Atrium Health

Toni K. Choueiri, MD—Chair
Dana-Farber Cancer Institute

John L. Gore, MD, MS
University of Washington Medical Center
Quality Metrics in Kidney Cancer Care

Panel Question and Answer

 

Case-Based Panel

Christian K. Kollmannsberger, MD
BC Cancer - Vancouver Cancer Centre
Medical Oncologist

Maxwell V. Meng, MD, FACS
University of California, San Francisco
Urologist

Thomas D. Atwell, MD
Mayo Clinic
Interventional Radiologist

Abstract 542: Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.
First Author: Laurence Albiges, MD, PhD

Panel Question and Answer